Khiron Life Sciences Corp (KHRNF)

[nowwhat2]

"Yeah, we're go go start up a marijuana company IN COLUMBIA S.A. !!!!!"........

SUCH business accumen !.......LoL

Yes.......The only thing holding it back is limitation on institutional buying.





.

[happyglass]

This is a company that is executing in spite of crazy regulations. The only thing holding it back is limitation on institutional buying. Only limited by the boughs schedule1 designation in the US. The instant that is removed this stock will do very well imo. American heavy handedness is being recognized for what it is. I am here, collecting when I can. This and other cos stuck in the same mire. Cannabis offers incredible opportunity for the patient

[steadykickin]

It's ashame, while it may have been necessary, the two previous UNANNOUNCED placement sale of stock were too much for this stock to overcome. VOLUME has become anemic as investors have become apathetic , a REVERSE SPLIT is necessary and inevitable for survival.

[Nosnibor]

100% agree. Khiron has a golden set-up and I wholeheartedly believe it is the best cannabis investment at this point.

[happyglass]

Nope. There will be no need to. This will fly. I am greatful for the early Holiday gift :)

https://www.newswire.ca/news-releases/khiron-begins-sales-in-switzerland-and-expands-its-medical-cannabis-portfolio-in-germany-and-the-united-kingdom-855788651.html

[steadykickin]

Reverse split coming here eventually. IMO.

[happyglass]

That has been my strategy too. My only regret is that I do not have more cash to put into it. It is one of my largest holdings and it is a better company now than it was when I bought it at a much higher price.

[Nosnibor]

Link didn't work for me, HG. Khiron is without question one of the most undervalued stocks out there in the global MJ space. I have been accumulating down for a long time..

[nowwhat2]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150667784

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150675716




.

[happyglass]

Q2 out soon. https://markets.qtrade.ca/stocks/overview?t=iKXJizM-dSY,RBgdWBB-F545YOIE8pSxiH4dqlAJ3zNr&symbol=CA:KHRN&rtl2=0&agreementVer=1&agreementDate=04/04/2017&status=N&sma=0&lang=en#

[nowwhat2]

Colombian elections......Underway ?

.

[Nosnibor]

Agreed. I have been adding regularly to my share count. Khiron are set up beautifully to make it however, very few actually know this yet. Bargain central at these low prices currently.

[happyglass]

It is unusual for the share price to be cheaper for retailers than a private offering. Very good opportunity in my opinion. Even with a bit of dilution. It gives them a cushion till the revenues start getting stronger. Averaging in as I can.

[yanquitrader]

KHIRON LIFE SCIENCES ANNOUNCES PRICING AND SIZE OF OVERNIGHT BROKERED OFFERING

Download as PDFJUNE 02, 2022 2:37PM EDT
/NOT FOR ?DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ?DISSEMINATION, DISTRIBUTION, ?RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES./

TORONTO, June 2, 2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has priced and sized its previously announced underwritten overnight marketed public offering (the "Offering"). Pursuant to the Offering, the Company will issue 26,700,000 units of the Company (each, a "Unit") at a price of C$0.15 per Unit (the "Offering Price") for aggregate gross proceeds of C$4,005,000. Each Unit will consist of one common share of the Company (each, a "Unit Share") and one Common Share purchase warrant of the Company (each, a "Unit Warrant"), with each Unit Warrant being exercisable to acquire one Common Share (each, a "Warrant Share") at an exercise price of C$0.20 for a period of 24 months following the closing date of the Offering.

[happyglass]

Here is the investor’s presentation from yesterday Q1 results.
https://seekingalpha.com/article/4515567-khiron-life-sciences-corp-khrnf-ceo-alvaro-torres-on-q1-2022-results-earnings-call-transcript

[nowwhat2]

Colombian elections sig. ?

.

[happyglass]

Here is the transcript of the investor presentation for year end 2021. They are focusing on medical cannabis and clinics. I am sad to see Kuida be put on the back burner but the CBD space is so saturated I think it is a very good move.
https://seekingalpha.com/article/4505892-khiron-life-sciences-khrnf-ceo-alvaro-torres-on-q4-2021-results-earnings-call-transcript

[Nosnibor]

Agreed. Exceptional loading & entry point here. Big future for Khiron..I do like Alvaro our CEO and believe he will see his shareholders right moving forward. His father is a successful executive too so that is a healthy dynamic in our favor.

[happyglass]

Yuuuup! And it seems to be our little secret I have no idea why there are not more people here.

[Nosnibor]

This is HUGE.

[nowwhat2]

The super-great Khiron Columbian weed co. !
Will ya' LOOK at this company FLY !

.

[nowwhat2]

The super-great Khiron Columbian weed co. !
Will ya' LOOK at this company FLY !

[happyglass]

Khiron has made an agreement to put Zerenia clinics in Mexican health centres

https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YOAM95G5jvZwZGoQbWAC&article=5a5bd081c3ba9ead#5a5bd081c3ba9ead


in Mexico
03/30/2022 07:15 AM ET
Teleton has 24 Medical Centers (22 rehabilitation centers, 1 autism center and 1 Children's Hospital for Cancer) located across the country, and around 600,000 patients with disability, cancer and autism conditions
The partnership includes:
-- Establishment of Khiron's Zerenia(TM) medical cannabis clinics within
Teleton's network across Mexico

-- Distribution of Khiron's medical cannabis products in Teleton's
pharmacies

-- Training of Teleton's Health Care Practitioners on delivery of medical
cannabis
TORONTO, March 30, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, has partnered with health care company Teleton to bring access to medical cannabis to more than 24 medical centers across Mexico.
Khiron is a leader in the marketplace with its end-to-end solution focusing on the category of medical cannabis. Khiron has a proprietary, sustainable model of growing, distributing, and prescribing cannabis for a range of health care solutions in its Zerenia (TM) medical cannabis clinics. Leveraging their wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and to drive prescriptions and brand loyalty with patients worldwide.
"The establishment of Khiron's Zerenia(TM) medical cannabis clinics in Teleton's medical centers is only the beginning of our go-to-market strategy and medical partnerships in Mexico," says Alvaro Torres, Khiron CEO and Director. "We are focused on delivering the highest quality and best care to patients and ongoing education to doctors and communities at large."
Khiron has also obtained regulatory quotas (authorization to use a control substance under International Conventions) from Mexico's regulatory agency COFEPRIS for importing CBD and THC into the country and is currently securing permits for imports to begin commercial sales in the country. With Mexico's population of nearly 130 million, it is among the top 15 economies worldwide, Khiron's serves more than 11.7 million people who have conditions treatable with medical cannabis.
Arturo Pichardo, Corporate Medical Director of Teleton, adds, "Teleton and Khiron's Zerenia(TM) clinic network complement each other perfectly with our strong patient focus, as we share the same values about our common mission. This partnership is good news for patients with various medical conditions throughout Mexico."
Khiron has also partnered with Mexico's top university Tecnologico de Monterrey to provide medical cannabis training to doctors across the country, based on Khiron's education programs and real-world evidence from its Zerenia(TM) clinics across Latin America.
About Teleton
Fundación Teletón is a non-profit organization that seeks to serve children with disabilities, cancer and autism, offering them comprehensive and quality care that promotes their full development and inclusion in society. In Mexico, it has 22 Rehabilitation Centers, 1 Autism Center and 1 Children's Hospital for Cancer, located across the country, and around 600,000 patients with disability, cancer and autism conditions attending since 1.999. It is part of ORITEL (The International Organization of Telethons), the integrating entity of 12 American countries (including the United States) that nowadays form part of the Telethon Organization which was created with the objective of providing and developing services of habilitation, rehabilitation and inclusion of children and adolescents with disabilities.
About Khiron Life Sciences Corp.
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, UK, Peru, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/

[happyglass]

Me too, it is my largest holding, not much compared tother folks but I am really happy here. Under water but smiling :) they have done everythjng they said they would and the clinics are brilliant.

[Nosnibor]

It is massive but no-one knows (it yet). Loading regularly.

[happyglass]

Khiron is partnering with Rappi to distribute their Kuida cbd products everywhere they have locations in LATAM. It is an agreement from 6months and from there potential to expand.
I like it! They do not even have to staff the booths. To me it seems to be an asset light way to reach customers.

Khiron will distribute the Kuida product line across LatAm through @RappiColombia!

The partnership allows Khiron to introduce its CBD products in every country where Rappi operates, increasing availability to millions of consumers:https://t.co/ZSUVrNWF6N pic.twitter.com/GzHJxXWE9o

— Alvaro Torres (@KhironLife) September 5, 2020

Rappi:

https://en.m.wikipedia.org/wiki/Rappi

[happyglass]

Ceo explains what is happening now the government is backing cannabis on its medical insurance


https://www.facebook.com/groups/206749766788545/permalink/1085965288866984/

[happyglass]

It gets better
:)
https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YOAH9Za9g_UIwaRr8uK5&article=1e2d245e1ed9f187#1e2d245e1ed9f187

Dow Jones
(PR) Mandatory Insurance Coverage for Medical Cannabis Now Expands to More than 50 million Colombians
01/04/2022 07:42 AM ET
-- Starting January 1st, 2022, every insurance provider in Colombia, is now
mandated to cover the costs of high and low THC medical cannabis
prescriptions

-- Significantly improves the current insurance coverage process,
simplifying the procedure and reducing approval times for patients to
obtain insurance coverage across the country

-- Colombia has upwards of 6 million potential patients for medical cannabis
products (Source: IMS Quintiles), and more than 97% of the population is
covered with health insurance

-- In 2021, the Company filled almost 52,000 medical cannabis prescriptions
in Colombia, 9 times more than in 2020. Over 60% of the product sales
were covered by insurance under the previous coverage rules
TORONTO, Jan. 4, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, announces that the Government of Colombia has added high and low THC medical cannabis to its list of mandated covered medications for every insurance provider in the country. This change will continue to cement Khiron's leadership position in the Colombian domestic medical cannabis market, leveraged by the Company's premium brand and its "seed to sale" medical cannabis clinic model.
"In March 2020, Khiron became the 1st licensed producer in Colombia to sell medical cannabis to patients through our wholly-owned clinics. Since then, the Company has continued to experience double-digit monthly growth and has exceeded more than 57,000 prescriptions sold to date, servicing more than 16,000 individual patients in the country and becoming a category leader in the Colombian medical cannabis industry. In December 2020, the Colombian government included medical cannabis as an approved medication for insurance coverage", commented Alvaro Torres, Khiron CEO, and Director.
"Since then, we have worked with insurance companies across the country to include this medication in their administrative systems. In 2021, 60% of our products were sold through agreements with two major insurance providers. Today, all insurance companies are mandated to cover medical cannabis in Colombia, with less paperwork and hassle for patients. Even though the previous rules were more complicated, the insurance coverage made a dramatic difference in our results:
KPI 2020 2021
# of prescribed patients /
Conversion Rate # of total consults 8% 32%
# of returning patients /
Retention Rate # of new + returning patients 33% 60%
Average monthly CAD spent per month per patient
transaction value on medical cannabis CAD 55 CAD 75
Total prescriptions # medical cannabis prescriptions
sold in Colombia sold 5,600 52,000
With the inclusion of medical cannabis in the mandatory health coverage plan ("POS"), we expect these trends to continue to grow further. Starting January 1(st) 2022, any patient in Colombia will be able to get their medical cannabis medication almost free of charge, regardless of the insurance company they are subscribed to. This unprecedented regulatory framework update will create one of the largest insured markets for medical cannabis in the world and help position Khiron as a leading company in this industry worldwide", added Mr. Torres.
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca

[slayer70]

I agree with the both of you I'm still holding long, but I'm not adding.

[Nosnibor]

I agree. Khiron has been laying the foundations (among the LATAM region which is in very early stage of the MJ space) and their success is underway. Khiron is also doing business with the UK and I think the first to do so which is massive. We haven't yet seen a spike in PPS but I am highly confident we will in due course. CEP Alvaro is a gentleman and from a family of good standing people (his father is CEO of a power company) - it is not in his DNA to run this OTCM stock like many scammers do. Success will follow and I am adding quite regularly.

[happyglass]

https://www.instagram.com/tv/CXTgQMnAy7X/?utm_medium=copy_link

[happyglass]

I like Khiron for their clinic model more than their growing capability. I hope they focus there. I prefer to own brands in this space now over growers. I just found a company that makes trichomes without a plant. That is the future. As an ingredient. There will always be premium paid for quality bud. But.. consistency is necessary for the next phase and it has arrived. Amazing how this has evolved in a few years. I think these guys have a shot. Still holding.

[slayer70]

Loading the boat here can make it sink.

[Nosnibor]

Loading the boat down here. Wow! I really do not see Alvaro letting us shareholders down.

[slayer70]

I want to be bullish on this one but it's hard to, when they did their last capital raise it really hurt this company, they went from 151.M shares to 179.1M in shares with a market cap of 38.5M that is so bad, and buying back 5% of shares what are they thinking (5% won't do anything for share price) keep the cash and put it to work. You also have to remember they're the smallest company in Columbia compared to other operators I'm still keeping my fingers crossed but it doesn't look good.

[Nosnibor]

I agree. Solid business with a highly committed CEO but flying so under the radar on a POS level. Khiron will rise in time. I truly believe this.

[happyglass]

Khiron had 83% gains year over year and over 20% Q over Q. Any other business that achieved that would be up crazy. Meanwhile Khiron languishes. That is okay! It gives me time to buy more

https://finance.yahoo.com/news/khiron-reports-q3-results-revenue-130000423.html

[nowwhat2]

ah yes - Here he is..... Lecturing others about ignorance....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162841379


Meranwhile ; https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166901471

[nowwhat2]

Boy, for it bein' such a great company, what do ya' figure ?
Hit's a nuther all time low today of .1613

Now just WHERE is that feller who used to mock me 'round here (for bein' so bearish towards 'em ?)

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=+khrnf&x=39&y=8&time=100&startdate=2%2F4%2F2021&enddate=1%2F23%2F2022&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9

[happyglass]

There is criminal activity going on but it is the politicians that are willfully destroying lives with criminalizing a benign plant that is the problem. I can accept their actions in the past as done in ignorance. Now they are doing it with a purpose to destroy other people’s lives and that is unacceptable

[trepid]

Can only laugh at the rising crime and violence part. How completely uninformed, inexperienced, and misguided that politician is.

[hdhick]

South Carolina Republican introduces bill to decriminalize marijuana at federal level

Rep. Nancy Mace, a first-term Republican from South Carolina, introduced a bill Monday to decriminalize cannabis at the federal level, which she hopes will garner more GOP support for the legalization movement.

"This legislation, I believe, has something good for everyone, whether you're a Democrat or a Republican," Mace told reporters outside the Capitol, where she introduced her States Reform Act.

Even though it is legal in 18 states, with medical use permissible in 37 states, marijuana is illegal under federal law.

Mace's bill would strip cannabis of its classification as a Schedule I drug under the Controlled Substances Act, which makes possession of marijuana a crime. Her office said the legislation aims to end criminalization "in a manner consistent with the rights of states to determine what level of cannabis reform or legalization each state wants to regulate, or not."

The measure also would allow for expungement of federal convictions in nonviolent cases and provide a framework for federal regulation and enforcement in states that allow the sale of marijuana.

Sales would be prohibited to people under 21, Mace said, adding that the bill would establish cannabis regulations similar to restrictions on alcohol.

The legislation further calls for a 3 percent federal excise tax on marijuana, lower than the level in a Democratic bill that is making its way through the House.

"I kept it very low," Mace said, pointing to high taxes on marijuana in California, which she said have stoked black market sales. "It's got to be under 4 percent to reduce the opportunity for illicit markets."


A Gallup poll released this month found that 68 percent of Americans support legalizing marijuana, with backing from 83 percent of Democrats and 50 percent of Republicans.

Mace said her bill already has five Republican co-sponsors.

"My main goal is to get as much Republican support as I can initially, and we're hearing great feedback," she said.

But the chair of the South Carolina GOP, Drew McKissick, denounced Mace's effort.

"Unequivocally, the South Carolina Republican Party is against any effort to legalize, decriminalize the use of controlled substances, and that includes this bill. Since this will have widespread negative impacts, from rising crime, violence, and mental health issues in children, I think it's a safe bet to say most Republicans will be against it too," McKissick said in a statement.

The Democratic-controlled House passed a broader but similar bill late last year called the Marijuana Opportunity Reinvestment and Expungement Act. A total of 222 Democrats and five Republicans voted for the legislation, while six Democrats and 158 Republicans voted against it.

The bill died in the Senate, which at the time was controlled by Republicans. House Democrats are trying to pass the legislation.

Senate Majority Leader Chuck Schumer, D-N.Y., circulated a draft bill this year that would decriminalize marijuana, called the Cannabis Administration and Opportunity Act, but he acknowledged he doesn't have the votes to get it passed. The legislation would need 60 votes to pass in the Senate, and a number of Republican and moderate Democratic senators have argued against quick action, urging further studies on the drug before it is decriminalized

[nowwhat2]

Khiron of Death Land....There's still meat on the bone.

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=khrnf&x=50&y=11&time=7&startdate=2%2F4%2F2020&enddate=11%2F23%2F2021&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9


https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=khrnf&x=59&y=18&time=100&startdate=2%2F4%2F2018&enddate=11%2F23%2F2021&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9

[Nosnibor]

Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

November 03, 2021 7:00am EDT

Zerenia™ Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK

Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic (www.zereniaclinic.co.uk) and will also offer in-person appointments with medical cannabis specialist practitioners

The new Zerenia™ location in UK brings Khiron's total global clinic count to 15 throughout Latin America and Europe and underscores its proven patient-centered approach

The implementation of the Company's clinic strategy will strengthen Khiron's European sales, which now account for 30% of the Company's total medical cannabis revenues for Q3 2021

TORONTO, Nov. 3, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the opening of Zerenia™ Clinics UK in London as its first International Zerenia™ clinic in Europe. This collectively brings the Company's total clinic count to 15 globally. Both virtual and in-person appointments can be made via the website www.zereniaclinic.co.uk.

Khiron Life Sciences Corp (CNW Group/Khiron Life Sciences Corp.)

Khiron in the United Kingdom
The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. The opening of Zerenia™ Clinics UK by an expert team is another step in this direction that expands Khiron's presence in Europe, where medical cannabis sales have grown more than 6x since Q1 2021. Even though Germany will continue to dominate the European market for medical cannabis until at least 2024, industry consultants Prohibition Partners expect the UK medical cannabis market to show the most significant growth of any country in Europe by 2025.

Zerenia™ Clinics UK will build upon Khiron's presence in the UK which started in 2019 when Khiron became a founding member and also the exclusive Latin American supplier for Project Twenty21 which offers a subsidized pricing model for patients in the program to help address barriers to access in the UK market. The Company continues to focus on medical training for healthcare professionals after receiving full Continuing Professional Development ("CPD") accreditation for its digital educational platform, Khiron Academy, and brings its proprietary clinical data generated in LatAm to the UK.

The Zerenia™ Clinic model
In the initial phase of operations, Zerenia™ Clinics UK will focus on pain management and will then expand its therapeutic portfolio to other areas such as mental health, women´s health, neurology and oncology. Though prominently located in London's famous Chelsea district, Zerenia™ Clinics UK will initially focus on supporting patients digitally (or via video-consultations) to enable streamlined access to patients across the UK, many of whom suffer from debilitating conditions. Zerenia™ Clinics UK follows the high-quality standards of personalised cannabinoid-based therapies and pursues precision-based medicine with the central goal to improve patient access to cannabinoid-based therapies.

In LatAm, the proven clinic model Zerenia™ is a patient-centered integrated care model combining traditional and complementary medicine with a focus on treatments with medical cannabis. The 14 Zerenia™ clinics in Colombia and Peru are known for their evidence-based treatments and highly professional applications with over 14,000 individual patients treated to date.

Franziska Katterbach, President Khiron Europe commented, "I am very excited about the opening of Zerenia™ Clinics UK in London with our very experienced local team. This is a great milestone for Khiron and will contribute significantly to the dynamics of developing a market for medical cannabis in the UK. From day one, it has been our goal to improve patient access to medical cannabis where suitable and also create evidence for the effectiveness and tolerability of medical cannabis; opening a UK cannabis clinic is just another logical step to serve patient's and clinician's needs."

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Linkedin at https://www.linkedin.com/company/khiron-life-sciences-corp/

[happyglass]

Excellent interview! Thank you for sharing

[Lc1980]

Former Mexican Predient Vicente Fox 2:26:56

[MoneyForNuthin]

$KHRNF Right there with you. Know what you own!

[Nosnibor]

Link to Khiron's Investor section https://investors.khiron.ca/investor-information

[Nosnibor]

Khiron to Present[color=red][/color] at Upcoming October Investor Conferences:

A.G.P.' S VIRTUAL FALL CONSUMER CANNABIS CONFERENCE
Attending 1x1 Meetings: Tuesday, October 5th 2021
Moderator: Aaron Grey, Managing Director, Equity Research Consumer & Cannabis

LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE
Khiron Presentation: Thursday, October 7th at 9:30 p.m. ET
Webcast: https://www.webcaster4.com/Webcast/Page/2783/42914

Panel "Growing without Borders, an International Perspective":
Thursday, October 7th at 11:30 p.m. ET
Webcast: https://www.meetmax.com/sched/event_75709/conference_register.html?bank_access=0&event_id=75709&attendee_role_id=INVESTOR

MJBIZ CONFERENCE
Thursday, October 15th at 4:00 p.m ET
Panel Participation: The Latin American Cannabis Supply Chain: Do's, Don'ts and Industry Domination

BENZINGA CANNABIS CAPITAL CONFERENCE
Marriott Marquis Hotel in New York City

Khiron Presentation: Friday, October 15th at 3:45 p.m ET
Virtual executive interview with Mr. Vicente Fox: Thursday, October 14th & 15th at 1:10 p.m ET
Panel: International Spotlight - Continued Cannabis Expansion in European Markets: Friday, October 15th at 2:10 p.m ET

A.G.P's hosted events are intended for prospective and existing A.G.P's clients only. To listen to the live event, please contact you're A.G.P's representative with interest.

For more information about the Lytham Partners Conference or to schedule a 1-on-1 meeting with Khiron, please contact a Lytham Partners representative at [e-mail] or register at www.lythampartners.com/fall2021invreg

Interested parties for the Benzinga Cannabis Capital Conference can register to attend here.

Members of the Khiron management will also be holding one-on-one investor meetings throughout the day. For more information about the conference or to schedule a 1-on-1 meeting with Khiron management, please call the company's investor relations team at 1-647-556-5750

Interested parties for the MJBizCon can register to attend here.

[Nosnibor]

Khiron is so under the radar rendering us investors very fortunate at this share price IMO. The future is bright and the CEO is both passionate and totally committed. Adding regularly to my holding.